z-logo
open-access-imgOpen Access
Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo
Author(s) -
Eleonora Ciarlo,
Tytti Hein,
Jacobus Herderscheê,
Craig Fenwick,
Matteo Mombelli,
Didier Le Roy,
Thierry Roger
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep37944
Subject(s) - in vivo , propionate , host (biology) , microbiology and biotechnology , short chain fatty acid , fatty acid , bacteria , biology , chemistry , biochemistry , ecology , fermentation , butyrate , genetics
Short chain fatty acids (SCFAs) produced by intestinal microbes mediate anti-inflammatory effects, but whether they impact on antimicrobial host defenses remains largely unknown. This is of particular concern in light of the attractiveness of developing SCFA-mediated therapies and considering that SCFAs work as inhibitors of histone deacetylases which are known to interfere with host defenses. Here we show that propionate, one of the main SCFAs, dampens the response of innate immune cells to microbial stimulation, inhibiting cytokine and NO production by mouse or human monocytes/macrophages, splenocytes, whole blood and, less efficiently, dendritic cells. In proof of concept studies, propionate neither improved nor worsened morbidity and mortality parameters in models of endotoxemia and infections induced by gram-negative bacteria ( Escherichia coli, Klebsiella pneumoniae ), gram-positive bacteria ( Staphylococcus aureus, Streptococcus pneumoniae ) and Candida albicans . Moreover, propionate did not impair the efficacy of passive immunization and natural immunization. Therefore, propionate has no significant impact on host susceptibility to infections and the establishment of protective anti-bacterial responses. These data support the safety of propionate-based therapies, either via direct supplementation or via the diet/microbiota, to treat non-infectious inflammation-related disorders, without increasing the risk of infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here